Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model | MarketScreener
Myriad’s MyRisk™ hereditary cancer test with RiskScore® provides personalized breast cancer risk assessment for women of all backgrounds SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more …